Donation Information

Donor Information

Just a moment while we process your donation 

If you’d like to make a credit card donation, please feel free to contact Gwyn Hulswit, HFM’s Associate Director at 734-544-0015. Or, if you’d prefer to make an offline donation, you may send a check to the following address:

Hemophilia Foundation of Michigan
Attention: Gwyn Hulswit
1921 W Michigan Avenue
Ypsilanti, MI 48197

Thank you for your generous donation. Your gift truly makes a difference.

Just a moment while we process your donation 
Please insert all the required fields
Please insert correct email
Please fill in a valid amount

Medical Advisory

Genentech Issues Statement on Hemlibra

Thursday, March 29, 2018

Genentech has released a statement to clarify the facts surrounding five people with hemophilia A with inhibitors to factor VIII who have passed away while receiving Hemlibra® (emicizumab-kxwh).

Read Genentech’s press release HERE.

If you have questions or concerns, please reach out to Genentech and/or your physician. Genentech has a Medical Communications line at (800) 821-8590 for patients, concerned community members, and healthcare providers who seek further information.


CSL Behring Discontinues Production and Distribution of Monoclate-P®

Tuesday, March 20, 2018

VIA The National Hemophilia Foundation:

CSL Behring has announced that due to patients transitioning from plasma-derived to recombinant products, it has been difficult to sustain the production and distribution of Antihemophilic Factor Monoclate-P® Factor VIII:C Pasteurized Monoclonal Antibody Purified. Therefore production of Monoclate-P® will be discontinued, and CSL Behring estimates that existing supplies will only be available until December 2018.

If you are currently using Monoclate-P®, please contact your physician or hemophilia treatment center to learn about other options that are available to you for treatment.

Alnylam Suspends Fitusiran Dosing due to Thrombotic Event

Thursday, September 7, 2017

VIA The Hemophilia Federation of America: Alnylam recently became aware of a fatal serious adverse event (SAE) that occurred in a patient with hemophilia A who was receiving fitusiran in the Phase 2 OLE study. As a result, the Company has suspended dosing in all ongoing fitusiran studies pending further review of the safety event and development of a risk mitigation strategy.

Click here for Alnylam’s full press release link is: Press Release